Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer

survival rate is only 28%. Currently, androgen deprivation therapy (ADT) via medical or surgical castration is the standard first-line therapy in men with metastatic disease but castration-recurrent

  • 1 views
  • 12 Mar, 2021
  • 1 location
Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate

The main objective of this study is to evaluate the response of erectile dysfunction in hypogonadotrophic males with Testosterone undecanoate i.m. as per IIEF and the question of the GAQ (Global Evaluation Questionnaire) after 42 weeks of treatment. Secondary Study Objectives - To monitor adverse events and changes in hemoglobin …

testosterone
hypogonadism
  • 209 views
  • 07 Nov, 2020
  • 2 locations
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)

This is a multicenter, open-label, randomized, two-arm, phase II clinical trial to evaluate the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in patients with metastatic hormone-nave prostate cancer (mHNPC)

ct scan
adenocarcinoma of prostate
bone scan
bone metastases
adenocarcinoma
  • 1 views
  • 30 May, 2021
  • 8 locations
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the body. Androgens can cause the growth of prostate cancer cells. Hormone …

abiraterone
measurable disease
tumor cells
adenocarcinoma of prostate
androgens
  • 1524 views
  • 11 May, 2021
  • 471 locations
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.

  • 0 views
  • 04 Aug, 2021
  • 1 location
Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients

We propose in this study to treat hormone refractory prostate cancer (HRPC) patients., with a novel preparation of fermented wheat germ nutriment (FWGE), in combination with the 1st line hormone therapy, the gonadotropin releasing hormone (GnRH), which stopped being effective. The study will be conducted during two years with 60 …

measurable disease
gonadotropin
endocrine therapy
hormone therapy
  • 4 views
  • 07 Nov, 2020
  • 1 location